News|Videos|November 22, 2023
Multidisciplinary Approaches in the Treatment of Low-Grade Serous Ovarian Cancer
Author(s)David O'Malley, MD
Dr O’Malley discusses strategies in collaborating with multidisciplinary teams for quality of life, fertility preservation, and management of treatment related side effects to optimize patient wellbeing.
Advertisement
Episodes in this series
Advertisement
Related to this article
With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
The estimated 3-year OS rate with botensilimab plus balstilimab was 48% in heavily pretreated recurrent ovarian cancer in the phase 1b C-800-01 trial.
A patient treated at the highest dose level of lira-cel to date had stable disease 90 days after infusion in a phase 1 trial in recurrent ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
5